X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Patient data for PGN-600 (tofacitinib) establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: PGN-600
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2022
Details:
Progenity is currently conducting preclinical studies to demonstrate the bioavailability of its lead candidates PGN-OB1 (adalimumab, delivered by the OBDS) and PGN-OB2 (liraglutide, a GLP-1 agonist, delivered by the OBDS).
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-OB1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
PGN-001 (liquid adalimumab delivered by DDS) is drug-device combination products being developed with an initial priority for ulcerative colitis.
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2021
Details:
The study evaluated delivery of Progenity’s drug-device combination PGN-001 (adalimumab) drug substance directly to colon in a preclinical model of colitis. Progenity advances towards clinical evaluation of adalimumab delivered by DDS in ulcerative colitis patients.
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
Initial analysis of the study results suggests PGN-600 was well tolerated, the DDS functioned as intended in the majority of doses, and resulted in significantly higher tofacitinib concentrations in colon tissue.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Gastroenterology Product Name: PGN-600
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
Funding from IBD Ventures will support further development and clinical studies of the DDS technology. Progenity’s lead candidates include PGN-001, a high-concentration formulation of adalimumab, and PGN-600, a high concentration, solubilized formulation of tofacitinib.
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Crohn’s & Colitis Foundation IBD Ventures Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2021
Details:
Progenity has two lead drug-device candidates utilizing the DDS technology, PGN-001, a high-concentration formulation of adalimumab, and PGN-600 a liquid formulation of tofacitinib, both under development for the treatment of ulcerative colitis.
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: PGN-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
